Ocuphire Pharma Investor Updates

P 16 Secondary Endpoint: % of Subjects ≥ 15 Letter Gain At All Timepoints Nyxol + LDP Had Strong Response With ≥ 15 Letter Gain From 30 Min To 6 Hours Percent of Subjects (%) 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subject with ≥ 15 Letters DCNVA Improvement from Baseline Binocular p=0.09 33% 16% 0 Rapid onset of efficacy p=<0.0001 14% 61% VEGA-1 Phase 2 Trial 0.5 p=0.003 28% 61% 1 p=<0.0001 Placebo (n=43) 16% 63% 2 Time (Hours) p=0.02 47% 21% 3 Nyxol+LDP (n=43) p=0.02 21% 47% 4 Durable benefit over 6 hours p=0.06 37% 19% со 6 Source: VEGA-1 TLR Table 14.2.1.2 Percent of Subjects with Improvement From Baseline in Photopic DCNVA by Time Point (PP Population). 15 letters is 3 lines. Ocuphire PHARMA

View entire presentation